BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 27535699)

  • 1. Pharmacological treatment of primary membranous nephropathy in 2016.
    van de Logt AE; Hofstra JM; Wetzels JF
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
    Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
    Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
    Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.
    Timmermans SA; Abdul Hamid MA; Cohen Tervaert JW; Damoiseaux JG; van Paassen P;
    Am J Nephrol; 2015; 42(1):70-7. PubMed ID: 26344651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
    Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Membranous nephropathy: Pathophysiology and natural history].
    Seitz-Polski B; Lambeau G; Esnault V
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.
    Teisseyre M; Perrochia H; Reboul P; Cariou S; Renaud S; Aglae C; Moranne O
    BMC Nephrol; 2020 May; 21(1):196. PubMed ID: 32448215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
    Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
    Guerry MJ; Vanhille P; Ronco P; Debiec H
    Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update].
    Pozdzik AA; Debiec H; I Brochériou ; Husson C; Rorive S; Broeders N; Le Moine A; Ronco P; Nortier J
    Rev Med Brux; 2015; 36(3):166-71. PubMed ID: 26372979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
    Segarra-Medrano A; Jatem-Escalante E; Carnicer-Cáceres C; Agraz-Pamplona I; Salcedo MT; Valtierra N; Ostos-Roldán E; Arredondo KV; Jaramillo J
    Nefrologia; 2014; 34(4):491-7. PubMed ID: 25036063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to immunosuppressive therapy in PLA
    Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
    BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.
    Glassock RJ
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1341-3. PubMed ID: 25035274
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances and prognosis in idiopathic membranous nephropathy.
    Segal PE; Choi MJ
    Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of idiopathic membranous nephropathy.
    Waldman M; Austin HA
    J Am Soc Nephrol; 2012 Oct; 23(10):1617-30. PubMed ID: 22859855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress on the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Wang C; Lu H; Yang C; Luo Y
    Chin Med J (Engl); 2014; 127(10):1960-3. PubMed ID: 24824263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins.
    Saito H; Hamasaki Y; Tojo A; Shintani Y; Shimizu A; Nangaku M
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():101-4. PubMed ID: 26031599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.